Currus Biologics is utilising its proprietary BEAT technology to develop CAR-T cell therapies for the treatment of solid tumour cancers, traditionally difficult to treat with current CAR-T cell therapies.
Currus Biologics’ proprietary Bispecific Engagers of Antigen Presenting Cells and T cells (BEAT) technology overcomes many of the challenges presented when treating solid tumours with traditional CAR-T cell therapy, demonstrating CAR-T cell proliferation and persistence, CAR-T cell trafficking to the tumour and immunological memory extending to additional antigens.
Currus Biologics is a privately held biotechnology company based in Melbourne, Australia.
Company Details
- Employees
- 9
- Founded
- -
- Address
- 31 Queen St, Melbourne,victoria 3000,australia
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- http://www.currusbio.com
- Keywords
- in a commercial setting.
- HQ
- Melbourne, Victoria
Currus Biologics Pty Ltd Questions
Currus Biologics Pty Ltd's website is http://www.currusbio.com
Currus Biologics Pty Ltd's LinkedIn profile is https://au.linkedin.com/company/currus-biologics-pty-ltd
Currus Biologics Pty Ltd has
9 employees.
View email and phone details for 9
employees at Currus Biologics Pty Ltd.
Currus Biologics Pty Ltd's industry is
Biotechnology Research
Currus Biologics Pty Ltd's top competitors are
Peter Maccallum Cancer Centre,
Occurx,
Mirugen,
Kinoxis Therapeutics Pty Ltd,
Oncores Medical,
Seetreat Medical,
Baymatob,
Certa Therapeutics,
Amplificare,
Externa.
Currus Biologics Pty Ltd's categories are Biotechnology Research
Currus Biologics Pty Ltd's founding year is 2021
